TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Vicore Pharma Holding AB ( (SE:VICO) ) has shared an update.
Vicore Pharma Holding AB has announced an increase in its number of shares and votes following a directed share issue, raising approximately USD 48 million. This development increases the company’s share capital and strengthens its financial position, potentially enhancing its ability to advance its drug development programs and maintain its competitive edge in the pharmaceutical industry.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing a novel class of drugs, particularly angiotensin II type 2 receptor agonists (ATRAGs), for treating respiratory and fibrotic diseases such as idiopathic pulmonary fibrosis (IPF). Their leading program, buloxibutid, is an oral small molecule that has received Orphan Drug and Fast Track designation from the FDA and is currently in a Phase 2b trial.
Average Trading Volume: 634,858
Technical Sentiment Signal: Sell
Current Market Cap: SEK2.4B
For detailed information about VICO stock, go to TipRanks’ Stock Analysis page.